M

Marvel Clinical Research | Huntington Beach, CA

Research site
(Unclaimed)
Location
17742 Beach Boulevard, suite 245, Huntington Beach, California, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

19 of 45
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Placebo
Drug: Ritlecitinib

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib 100 mg
Drug: Ritlecitinib

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling
Hypertension
Drug: lorundrostat Dose 2
Drug: lorundrostat Dose 1

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Active, not recruiting
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

The purpose of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine compo...

Active, not recruiting
Influenza
SARS-CoV-2
Biological: mRNA-1083.1
Biological: mRNA-1010

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib
Locations recently updated

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Topical corticosteroids

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Enrolling
COVID-19
Influenza
Biological: Placebo
Biological: Influenza and COVID-19 Combination B

The purpose of this study is to learn about the safety and effects of sisunatovir. Sisunatovir is studied for the possible treatment of Respiratory S...

Enrolling
Respiratory Syncytial Virus Infection
Drug: Sisunatovir
Drug: Placebo

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: PF-07264660

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

To evaluate the long-term safety and tolerability of oral dersimelagon.

Active, not recruiting
EPP
XLP
Drug: MT-7117

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated...

Enrolling
X-Linked Protoporphyria (XLP)
Erythropoietic Protoporphyria (EPP)
Drug: Dersimelagon
Drug: Placebo

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Enrolling
OSA
Drug: Placebo
Drug: AD109

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: Placebo
Biological: RSVpreF

This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately...

Active, not recruiting
Influenza, Human
Biological: licensed QIV1
Biological: licensed QIV2

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CH...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Trial conditions

Human Influenza (6 trials)
Vitiligo (5 trials)
Eczema (4 trials)
Erythropoietic Protoporp... (3 trials)
Hot Flashes (3 trials)
Hypertension (3 trials)
Atopic Dermatitis (2 trials)
COVID-19 (2 trials)
Communicable Diseases (2 trials)
Dermatitis (2 trials)

And 24 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems